petition from t315i patients on the web, page-8

biotek

I've read the transcript. Maybe I will watch the podcast.

TKI resistance is a growing problem. Estimates are 200-500 in US alone. T315I means that TKIs are ineffective - so imatinib and other 2nd line therapies can no longer inhibit the tyrosine kinas from causing the disease in the first place.

You cannot compare TKIs with Omapro. Omapro works differently to existing therapies. So if you have the T315I mutation, that means that the tyrosine kinas which cause CML in the first place are working full-time again. Response rates will be expected to be lower than current TKIs. Don't trust me, talk to CML scientists/therapists in the community for an opinion on that.